Efeito antimaniaco do tamoxifeno em modelo animal /

Orientador : Prof. Dr. Roberto AndreatiniDissertação (mestrado) - Universidade Federal do Paraná, Setor de Ciências Biológicas, Programa de Pós-Graduação em Farmacologia. Defesa: Curitiba, 2007Inclui bibliografi

Efeito antimaniaco do tamoxifeno em modelo animal /

Orientador : Prof. Dr. Roberto AndreatiniDissertação (mestrado) - Universidade Federal do Paraná, Setor de Ciências Biológicas, Programa de Pós-Graduação em Farmacologia. Defesa: Curitiba, 2007Inclui bibliografi

Psychosocial and pharmacological interventions for the treatment of cannabis use disorder [version 1; referees: 3 approved]

Cannabis use has been continuously increasing, and cannabis use disorder (CUD) has become a public health issue. Some psychosocial interventions have demonstrated the ability to reduce cannabis use; however, there are no pharmacotherapies approved for the treatment of CUD. Some drugs have shown limited positive effects on use and withdrawal symptoms, but no controlled studies have been able to show strong and persistent effects on clinically meaningful outcomes. The aim of this review is to synthesize the evidence from the available literature regarding the effectiveness of psychosocial and pharmacological treatments for CUD among adults (that is, 18 years old or older). An analysis of the evidence shows that the current best psychosocial intervention to reduce cannabis use is the combination of motivational enhancement therapy and cognitive-behavioral therapy, preferably accompanied by a contingency management approach. In regard to pharmacological interventions, there are mostly unclear findings. Some drugs, such as CB1 agonists, gabapentin, and N-acetylcysteine, have been shown to produce improvements in some symptoms of CUD in single studies, but these have not been replicated. Other classes of medications, including antidepressants and antipsychotics, have been unsuccessful in producing such effects. There is an imminent need for more clinical trials to develop more effective treatments for CUD

The Effectiveness of Treatments for Cocaine Dependence in Schizophrenic Patients: A Systematic Review

Objectives: To evaluate and compare the effectiveness of available treatments for cocaine dependence in schizophrenic patients.Method: We searched articles published between May 2002 and June 2012 in the following databases: Scopus, Pubmed and Web of Knowledge. The key words utilised were schizophrenia, dementia praecox, schizophrenic disorder, cocaine related disorder, cocaine abuse, cocaine addiction, cocaine dependence, treatment, therapeutic, and drug therapy.Selection of studies and data extraction: Original articles in English, Portuguese and Spanish were selected. Controlled, double-blind and open-label studies involving only human subjects were included in this review.Data Synthesis: We found studies on typical and atypical antipsychotics and one monoamine transporter antagonist. There were few indications of the effectiveness of atypical antipsychotic medications for the treatment of cocaine dependence in patients with schizophrenia.Conclusions: We suggest that further studies be conducted with atypical antipsychotic medicationsand greater methodological strictness, including using a placebo group in the studies, so that health professionals can determine the real effectiveness of this class of medication for the treatment of cocaine dependence in schizophrenic patients.Univ Fed Sao Paulo, Dept Psychobiol, BR-04024002 Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Psychobiol, BR-04024002 Sao Paulo, BrazilWeb of Scienc

Psychosocial interventions for cannabis use disorder

Paper 35Peter Gates, Pamela Sabioni, Jan Copeland, Bernard Le Foll and Linda Gowin

Mal/adaptations: A qualitative evidence synthesis of opioid agonist therapy during major disruptions

Opioid agonist therapy (OAT) has been severely disrupted by the COVID-19 pandemic. The risks of opioid withdrawal, overdose, and diversion have increased, so there is an urgent need to adapt OAT to best support people who use drugs (PWUD). This review examines the views and experiences of PWUD, health care providers, and health system administrators on OAT during major disruptions to medical care to inform appropriate health system responses during the current pandemic and beyond.This review was completed with funding support from the Canadian Institutes of Health Research Operating Grant: Knowledge Synthesis: COVID-19 in Mental Health and Substance Use [reference number: CMS-171725]. The funding source had no involvement in study design, data collection, analysis, interpretation, report writing, or decision to submit